Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
88% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. KERX: No Debt )
KERX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.71
KERX's Equity to Asset is ranked higher than
82% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. KERX: 0.71 )
KERX' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.9
Current: 0.71

-0.06
0.9
Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
67% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KERX: No Debt )
KERX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 15.01
M-Score: -3.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1027.52
KERX's Operating margin (%) is ranked higher than
59% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. KERX: -1027.52 )
KERX' s 10-Year Operating margin (%) Range
Min: -15010.67   Max: 38.97
Current: -1027.52

-15010.67
38.97
Net-margin (%) -1030.19
KERX's Net-margin (%) is ranked higher than
58% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. KERX: -1030.19 )
KERX' s 10-Year Net-margin (%) Range
Min: -13813.48   Max: 41.62
Current: -1030.19

-13813.48
41.62
ROE (%) -114.77
KERX's ROE (%) is ranked higher than
60% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. KERX: -114.77 )
KERX' s 10-Year ROE (%) Range
Min: -429.23   Max: 68.51
Current: -114.77

-429.23
68.51
ROA (%) -93.79
KERX's ROA (%) is ranked higher than
58% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. KERX: -93.79 )
KERX' s 10-Year ROA (%) Range
Min: -323.38   Max: 31.09
Current: -93.79

-323.38
31.09
ROC (Joel Greenblatt) (%) -11514.39
KERX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. KERX: -11514.39 )
KERX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46369.35   Max: 7114.49
Current: -11514.39

-46369.35
7114.49
Revenue Growth (3Y)(%) 19.70
KERX's Revenue Growth (3Y)(%) is ranked lower than
114% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. KERX: 19.70 )
KERX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 268.4
Current: 19.7

0
268.4
EBITDA Growth (3Y)(%) 41.60
KERX's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. KERX: 41.60 )
KERX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.1   Max: 71.3
Current: 41.6

-45.1
71.3
EPS Growth (3Y)(%) 43.10
KERX's EPS Growth (3Y)(%) is ranked higher than
88% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. KERX: 43.10 )
KERX' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.5   Max: 60
Current: 43.1

-44.5
60
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

KERX Guru Trades in Q1 2014

Jim Simons 18,700 sh (New)
Steven Cohen 1,525,058 sh (New)
Pioneer Investments 284,299 sh (New)
Seth Klarman 6,310,850 sh (New)
» More
Q2 2014

KERX Guru Trades in Q2 2014

Seth Klarman 10,539,986 sh (+67.01%)
Steven Cohen 1,247,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
» More
Q3 2014

KERX Guru Trades in Q3 2014

Seth Klarman 18,300,000 sh (+73.62%)
Steven Cohen Sold Out
» More
Q4 2014

KERX Guru Trades in Q4 2014

Seth Klarman 18,300,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-09-30 Add 73.62%1.87%$12.71 - $18.19 $ 13.26-13%18300000
Seth Klarman 2014-06-30 Add 67.01%1.04%$12.11 - $17.03 $ 13.26-6%10539986
Seth Klarman 2014-03-31 New Buy2.6%$12.16 - $16.88 $ 13.26-12%6310850
John Burbank 2012-12-31 Sold Out 0.06%$2.31 - $3.14 $ 13.26388%0
John Burbank 2012-09-30 New Buy0.06%$1.79 - $2.83 $ 13.26538%500000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Baupost’s Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd Gaming, Theravance
Renowned value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his third quarter portfolio. Seth Klarman (Trades, Portfolio) buys Cheniere Energy Inc, Ocwen Financial Corp, Antero Resources Corp, Veritiv Corp, Keryx Biopharmaceuticals Inc, eBay Inc, PBF Energy Inc, Forward Pharma AS, PBF Energy Inc, Atara Biotherapeutics Inc, sells Boyd Gaming Corporation, Theravance Inc, Syneron Medical Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 09/30/2014, The Baupost Group owns 27 stocks with a total value of $5.7 billion. These are the details of the buys and sells. Read more...
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sells BP, Theravance
Legendary value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his second quarter portfolio. Seth Klarman (Trades, Portfolio) buys eBay Inc, SunEdison Semiconductor Ltd, Keryx Biopharmaceuticals Inc, Kosmos Energy Ltd, Boyd Gaming Corporation, Triquint Semiconductor, RF Micro Devices Inc, Cheniere Energy Inc, Viasat Inc, Veritiv Corp, Veritiv Corp, sells BP PLC, Theravance Inc during the 3-months ended 06/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 06/30/2014, The Baupost Group owns 24 stocks with a total value of $6.1 billion. These are the details of the buys and sells. Read more...
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals
The Baupost Group’s Seth Klarman (Trades, Portfolio) has purchased a new holding that constitutes more than 5% of the company, requiring reporting during the quarter and appearing on GuruFocus RealTime Picks. The purchase was of 9,151,600 shares of Keryx Biopharmaceuticals (KERX), which represents 10.07% of the company’s shares outstanding. Read more...
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD
According to GuruFocus Insider Data, the largest insider sells during the past week were: Keryx Biopharmaceuticals Inc., Oracle Corporation, Qualcomm Inc. and Gilead Sciences Inc. Read more...

Ratios

vs
industry
vs
history
Forward P/E 31.15
KERX's Forward P/E is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: 31.15 )
N/A
P/B 17.00
KERX's P/B is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. KERX: 17.00 )
KERX' s 10-Year P/B Range
Min: 1.88   Max: 49
Current: 17

1.88
49
P/S 111.00
KERX's P/S is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. KERX: 111.00 )
KERX' s 10-Year P/S Range
Min: 1.1   Max: 1911
Current: 111

1.1
1911
EV-to-EBIT -10.07
KERX's EV-to-EBIT is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: -10.07 )
KERX' s 10-Year EV-to-EBIT Range
Min: -29.7   Max: 54.6
Current: -10.07

-29.7
54.6
Current Ratio 3.36
KERX's Current Ratio is ranked higher than
72% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. KERX: 3.36 )
KERX' s 10-Year Current Ratio Range
Min: 1.88   Max: 35.68
Current: 3.36

1.88
35.68
Quick Ratio 3.10
KERX's Quick Ratio is ranked higher than
74% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. KERX: 3.10 )
KERX' s 10-Year Quick Ratio Range
Min: 1.88   Max: 35.68
Current: 3.1

1.88
35.68
Days Inventory 1.00
KERX's Days Inventory is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: 1.00 )
KERX' s 10-Year Days Inventory Range
Min: 2886.82   Max: 2886.82
Current: 1

Days Sales Outstanding 28.12
KERX's Days Sales Outstanding is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. KERX: 28.12 )
KERX' s 10-Year Days Sales Outstanding Range
Min: 0.51   Max: 2248.5
Current: 28.12

0.51
2248.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.73
KERX's Price/Net Cash is ranked higher than
82% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. KERX: 21.73 )
KERX' s 10-Year Price/Net Cash Range
Min: 1.49   Max: 29.11
Current: 21.73

1.49
29.11
Price/Net Current Asset Value 20.06
KERX's Price/Net Current Asset Value is ranked higher than
81% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. KERX: 20.06 )
KERX' s 10-Year Price/Net Current Asset Value Range
Min: 1.46   Max: 29.11
Current: 20.06

1.46
29.11
Price/Tangible Book 17.16
KERX's Price/Tangible Book is ranked higher than
70% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. KERX: 17.16 )
KERX' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 26.2
Current: 17.16

0.93
26.2
Price/Median PS Value 1.22
KERX's Price/Median PS Value is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. KERX: 1.22 )
KERX' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 16.45
Current: 1.22

0.05
16.45
Earnings Yield (Greenblatt) -9.60
KERX's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. KERX: -9.60 )
KERX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 27616.5
Current: -9.6

1.8
27616.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals, Inc., was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for KERX

Headlines

Articles On GuruFocus.com
Portfolio Feb 16 2015 
2015 Must-Buys In Biotech Sector Feb 02 2015 
me Jan 23 2015 
Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
Baupost’s Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd Gaming, Nov 14 2014 
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sel Aug 14 2014 
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD Mar 24 2014 
Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ Jan 06 2014 


More From Other Websites
Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal... Mar 04 2015
Keryx Announces Fourth Quarter and Year-End 2014 Financial Results Mar 04 2015
Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal... Mar 04 2015
Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog Mar 02 2015
Keryx Spotlights Biotech Challenge Mar 02 2015
Overheard: Keryx’s Value in Profits Mar 02 2015
Keryx's (KERX) Q4 Loss Misses Expectation, Auryxia in Focus - Tale of the Tape Feb 27 2015
Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Feb 27 2015
Keryx Biopharma reports 4Q loss Feb 27 2015
Keryx Biopharma reports 4Q loss Feb 27 2015
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences Feb 27 2015
Q4 2014 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open Feb 27 2015
Keryx Announces Fourth Quarter and Year-End 2014 Financial Results Feb 27 2015
What Awaits Keryx Biopharmaceuticals (KERX) this Earnings? - Analyst Blog Feb 26 2015
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial... Feb 25 2015
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences Feb 25 2015
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2014 Financial... Feb 18 2015
Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch Feb 09 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 27 2015
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Jan 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK